Last 12 months
Inside the activity.
3 purchase rows · 2 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 1 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 3 | 1 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 26, 2021 Filed Nov 30, 2021 21:30 UTC |
LANKLER DOUGLAS MExecutive Vice President
|
SaleCommon Stock | 1,677 | $54.46 | $91,329.42 |
DisclosureSEC source: 0001225208-21-014220 · doc4.xml · nonDerivative · entry 5 LANKLER DOUGLAS M · CIK 0001488270 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,977 Read SEC document |
| November 26, 2021 Filed Nov 30, 2021 21:30 UTC |
LANKLER DOUGLAS MExecutive Vice President
|
SaleCommon Stock | 1,497 | $54.47 | $81,541.59 |
DisclosureSEC source: 0001225208-21-014220 · doc4.xml · nonDerivative · entry 4 LANKLER DOUGLAS M · CIK 0001488270 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,654 Read SEC document |
| November 26, 2021 Filed Nov 30, 2021 21:30 UTC |
LANKLER DOUGLAS MExecutive Vice President
|
SaleCommon Stock | 1,133 | $54.26 | $61,476.58 |
DisclosureSEC source: 0001225208-21-014220 · doc4.xml · nonDerivative · entry 3 LANKLER DOUGLAS M · CIK 0001488270 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,151 Read SEC document |
| November 26, 2021 Filed Nov 30, 2021 21:30 UTC |
LANKLER DOUGLAS MExecutive Vice President
|
SaleCommon Stock | 909 | $54.45 | $49,495.05 |
DisclosureSEC source: 0001225208-21-014220 · doc4.xml · nonDerivative · entry 2 LANKLER DOUGLAS M · CIK 0001488270 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,284 Read SEC document |
| November 26, 2021 Filed Nov 30, 2021 21:30 UTC |
LANKLER DOUGLAS MExecutive Vice President
|
SaleCommon Stock | 124 | $54.32 | $6,735.68 |
DisclosureSEC source: 0001225208-21-014220 · doc4.xml · nonDerivative · entry 1 LANKLER DOUGLAS M · CIK 0001488270 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,193 Read SEC document |
| November 15, 2021 Filed Nov 16, 2021 22:36 UTC |
BOURLA ALBERTDirector · Chairman & CEO
|
GrantPhantom Stock Units SSP · Derivative | 10 | $49.65 | $496.50 |
DisclosureSEC source: 0001225208-21-013900 · doc4.xml · derivative · entry 1 BOURLA ALBERT · CIK 0001595703 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,983 Underlying: Common Stock · 10 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| November 15, 2021 Filed Nov 16, 2021 22:36 UTC |
DAMICO JENNIFER B.SVP & Controller
|
GrantPhantom Stock Units SSP · Derivative | 25 | $49.65 | $1,241.25 |
DisclosureSEC source: 0001225208-21-013901 · doc4.xml · derivative · entry 1 DAMICO JENNIFER B. · CIK 0001805617 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,229 Underlying: Common Stock · 25 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| November 15, 2021 Filed Nov 16, 2021 22:36 UTC |
JOHNSON RADY AExecutive Vice President
|
GrantPhantom Stock Units SSP · Derivative | 3 | $49.65 | $148.95 |
DisclosureSEC source: 0001225208-21-013902 · doc4.xml · derivative · entry 1 JOHNSON RADY A · CIK 0001594762 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,753 Underlying: Common Stock · 3 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| November 15, 2021 Filed Nov 16, 2021 22:37 UTC |
YOUNG JOHN DGroup President
|
GrantPhantom Stock Units SSP · Derivative | 9 | $49.65 | $446.85 |
DisclosureSEC source: 0001225208-21-013903 · doc4.xml · derivative · entry 1 YOUNG JOHN D · CIK 0001551792 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,698 Underlying: Common Stock · 9 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| November 12, 2021 Filed Nov 15, 2021 22:32 UTC |
Hwang AngelaGroup President
|
OtherPhantom Stock Units SSP · Derivative | 18,098 | $49.73 | $900,013.54 |
DisclosureSEC source: 0001225208-21-013881 · doc4.xml · derivative · entry 7 Hwang Angela · CIK 0001725474 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,576 Underlying: Common Stock · 18,098 shares Expires not disclosed F2 · derivative.exercise_price: Each unit represents one phantom share of common stock. F3 · shares: This transaction constitutes an intra-plan transfer into the Pfizer stock unit fund under the Pfizer Inc. Supplemental Savings Plan. F4 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F4 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| November 12, 2021 Filed Nov 15, 2021 22:32 UTC |
Hwang AngelaGroup President
|
SaleCommon Stock | 11,312 | $49.60 | $561,075.20 |
DisclosureSEC source: 0001225208-21-013881 · doc4.xml · nonDerivative · entry 4 Hwang Angela · CIK 0001725474 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1 Read SEC document |
| November 12, 2021 Filed Nov 15, 2021 22:32 UTC |
Hwang AngelaGroup President
|
SaleCommon Stock | 10,646 | $49.59 | $527,935.14 |
DisclosureSEC source: 0001225208-21-013881 · doc4.xml · nonDerivative · entry 3 Hwang Angela · CIK 0001725474 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,313 Read SEC document |
| November 12, 2021 Filed Nov 15, 2021 22:32 UTC |
Hwang AngelaGroup President
|
SaleCommon Stock | 3,412 | $49.62 | $169,303.44 |
DisclosureSEC source: 0001225208-21-013881 · doc4.xml · nonDerivative · entry 2 Hwang Angela · CIK 0001725474 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,959 Read SEC document |
| November 12, 2021 Filed Nov 15, 2021 22:32 UTC |
Hwang AngelaGroup President
|
SaleCommon Stock | 800 | $49.61 | $39,688.00 |
DisclosureSEC source: 0001225208-21-013881 · doc4.xml · nonDerivative · entry 1 Hwang Angela · CIK 0001725474 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,371 Read SEC document |
| November 11, 2021 Filed Nov 12, 2021 23:08 UTC |
YOUNG JOHN DGroup President
|
SaleCommon Stock | 47,782 | $50.01 | $2,389,577.82 |
DisclosureSEC source: 0001225208-21-013850 · doc4.xml · nonDerivative · entry 11 YOUNG JOHN D · CIK 0001551792 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 312,704 Read SEC document |
| November 11, 2021 Filed Nov 12, 2021 23:08 UTC |
YOUNG JOHN DGroup President
|
SaleCommon Stock | 30,200 | $50.02 | $1,510,604.00 |
DisclosureSEC source: 0001225208-21-013850 · doc4.xml · nonDerivative · entry 10 YOUNG JOHN D · CIK 0001551792 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 360,486 Read SEC document |
| November 11, 2021 Filed Nov 12, 2021 23:08 UTC |
YOUNG JOHN DGroup President
|
SaleCommon Stock | 15,500 | $50.12 | $776,860.00 |
DisclosureSEC source: 0001225208-21-013850 · doc4.xml · nonDerivative · entry 9 YOUNG JOHN D · CIK 0001551792 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 390,686 Read SEC document |
| November 11, 2021 Filed Nov 12, 2021 23:08 UTC |
YOUNG JOHN DGroup President
|
SaleCommon Stock | 11,700 | $50.10 | $586,170.00 |
DisclosureSEC source: 0001225208-21-013850 · doc4.xml · nonDerivative · entry 8 YOUNG JOHN D · CIK 0001551792 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 406,186 Read SEC document |
| November 11, 2021 Filed Nov 12, 2021 23:08 UTC |
YOUNG JOHN DGroup President
|
SaleCommon Stock | 9,818 | $50.07 | $491,587.26 |
DisclosureSEC source: 0001225208-21-013850 · doc4.xml · nonDerivative · entry 7 YOUNG JOHN D · CIK 0001551792 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 417,886 Read SEC document |
| November 11, 2021 Filed Nov 12, 2021 23:08 UTC |
YOUNG JOHN DGroup President
|
SaleCommon Stock | 9,500 | $50.15 | $476,425.00 |
DisclosureSEC source: 0001225208-21-013850 · doc4.xml · nonDerivative · entry 6 YOUNG JOHN D · CIK 0001551792 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 427,704 Read SEC document |
| November 11, 2021 Filed Nov 12, 2021 23:08 UTC |
YOUNG JOHN DGroup President
|
SaleCommon Stock | 9,100 | $50.14 | $456,274.00 |
DisclosureSEC source: 0001225208-21-013850 · doc4.xml · nonDerivative · entry 5 YOUNG JOHN D · CIK 0001551792 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 437,204 Read SEC document |
| November 11, 2021 Filed Nov 12, 2021 23:08 UTC |
YOUNG JOHN DGroup President
|
SaleCommon Stock | 6,200 | $50.06 | $310,372.00 |
DisclosureSEC source: 0001225208-21-013850 · doc4.xml · nonDerivative · entry 4 YOUNG JOHN D · CIK 0001551792 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 446,304 Read SEC document |
| November 11, 2021 Filed Nov 12, 2021 23:08 UTC |
YOUNG JOHN DGroup President
|
SaleCommon Stock | 4,200 | $50.03 | $210,126.00 |
DisclosureSEC source: 0001225208-21-013850 · doc4.xml · nonDerivative · entry 3 YOUNG JOHN D · CIK 0001551792 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 452,504 Read SEC document |
| November 11, 2021 Filed Nov 12, 2021 23:08 UTC |
YOUNG JOHN DGroup President
|
SaleCommon Stock | 3,200 | $50.09 | $160,288.00 |
DisclosureSEC source: 0001225208-21-013850 · doc4.xml · nonDerivative · entry 2 YOUNG JOHN D · CIK 0001551792 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 456,704 Read SEC document |
| November 11, 2021 Filed Nov 12, 2021 23:08 UTC |
YOUNG JOHN DGroup President
|
SaleCommon Stock | 2,800 | $50.16 | $140,448.00 |
DisclosureSEC source: 0001225208-21-013850 · doc4.xml · nonDerivative · entry 1 YOUNG JOHN D · CIK 0001551792 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 459,904 Read SEC document |
| November 11, 2021 Filed Nov 15, 2021 22:40 UTC |
Dolsten MikaelPresident R&D
|
Exercise / conversionStock Appreciation Rights · Derivative | 127,160 | $0.00 Strike: $25.60 | $0.00 |
DisclosureSEC source: 0001225208-21-013883 · doc4.xml · derivative · entry 15 Dolsten Mikael · CIK 0001437590 · President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 127,160 shares Expires 2022-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 11, 2021 Filed Nov 15, 2021 22:40 UTC |
Dolsten MikaelPresident R&D
|
Exercise / conversionStock Appreciation Rights · Derivative | 145,970 | $0.00 Strike: $22.89 | $0.00 |
DisclosureSEC source: 0001225208-21-013883 · doc4.xml · derivative · entry 14 Dolsten Mikael · CIK 0001437590 · President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 145,970 shares Expires 2023-02-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 11, 2021 Filed Nov 15, 2021 22:40 UTC |
Dolsten MikaelPresident R&D
|
Exercise / conversionStock Appreciation Rights · Derivative | 153,789 | $0.00 Strike: $27.34 | $0.00 |
DisclosureSEC source: 0001225208-21-013883 · doc4.xml · derivative · entry 13 Dolsten Mikael · CIK 0001437590 · President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 153,789 shares Expires 2022-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 11, 2021 Filed Nov 15, 2021 22:40 UTC |
Dolsten MikaelPresident R&D
|
OtherPhantom Stock Units · Derivative | 47,828 | $50.18 | $2,400,009.04 |
DisclosureSEC source: 0001225208-21-013883 · doc4.xml · derivative · entry 12 Dolsten Mikael · CIK 0001437590 · President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,314 Underlying: Common Stock · 47,828 shares Expires not disclosed F3 · derivative.exercise_price: Each unit represents one phantom share of common stock. F4 · shares: The reporting person diversified shares held in the Pfizer Inc. Deferred Compensation Plan ("Plan") pursuant to the Plan's diversification provision into an alternate investment option(s) under the Plan. F5 · derivative.exercise_date: The units, held under the Deferred Compensation Plan, are paid in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F5 · derivative.expiration_date: The units, held under the Deferred Compensation Plan, are paid in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| November 11, 2021 Filed Nov 15, 2021 22:40 UTC |
Dolsten MikaelPresident R&D
|
SaleCommon Stock | 36,711 | $50.28 | $1,845,829.08 |
DisclosureSEC source: 0001225208-21-013883 · doc4.xml · nonDerivative · entry 10 Dolsten Mikael · CIK 0001437590 · President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 279,842 Read SEC document |
| November 11, 2021 Filed Nov 15, 2021 22:40 UTC |
Dolsten MikaelPresident R&D
|
SaleCommon Stock | 6,708 | $50.33 | $337,613.64 |
DisclosureSEC source: 0001225208-21-013883 · doc4.xml · nonDerivative · entry 9 Dolsten Mikael · CIK 0001437590 · President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 316,553 Read SEC document |
| November 11, 2021 Filed Nov 15, 2021 22:40 UTC |
Dolsten MikaelPresident R&D
|
SaleCommon Stock | 5,227 | $50.29 | $262,865.83 |
DisclosureSEC source: 0001225208-21-013883 · doc4.xml · nonDerivative · entry 8 Dolsten Mikael · CIK 0001437590 · President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 323,261 Read SEC document |
| November 11, 2021 Filed Nov 15, 2021 22:40 UTC |
Dolsten MikaelPresident R&D
|
SaleCommon Stock | 3,396 | $50.31 | $170,852.76 |
DisclosureSEC source: 0001225208-21-013883 · doc4.xml · nonDerivative · entry 7 Dolsten Mikael · CIK 0001437590 · President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 328,488 Read SEC document |
| November 11, 2021 Filed Nov 15, 2021 22:40 UTC |
Dolsten MikaelPresident R&D
|
SaleCommon Stock | 3,197 | $50.29 | $160,777.13 |
DisclosureSEC source: 0001225208-21-013883 · doc4.xml · nonDerivative · entry 6 Dolsten Mikael · CIK 0001437590 · President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 331,884 Read SEC document |
| November 11, 2021 Filed Nov 15, 2021 22:40 UTC |
Dolsten MikaelPresident R&D
|
SaleCommon Stock | 2,301 | $50.32 | $115,786.32 |
DisclosureSEC source: 0001225208-21-013883 · doc4.xml · nonDerivative · entry 5 Dolsten Mikael · CIK 0001437590 · President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 335,081 Read SEC document |
| November 11, 2021 Filed Nov 15, 2021 22:40 UTC |
Dolsten MikaelPresident R&D
|
SaleCommon Stock | 2,124 | $50.34 | $106,922.16 |
DisclosureSEC source: 0001225208-21-013883 · doc4.xml · nonDerivative · entry 4 Dolsten Mikael · CIK 0001437590 · President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 337,382 Read SEC document |
| November 11, 2021 Filed Nov 15, 2021 22:40 UTC |
Dolsten MikaelPresident R&D
|
Exercise / conversionCommon Stock | 58,572 | $25.60 | $1,499,443.20 |
DisclosureSEC source: 0001225208-21-013883 · doc4.xml · nonDerivative · entry 3 Dolsten Mikael · CIK 0001437590 · President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 339,506 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the number of stock units received upon the exercise and conversion of previously granted stock appreciation rights (SARs), calculated by taking the change in Pfizer common stock price (20 trading day average ending on the exercise date (Election Price of $44.58)) less the grant price of the SAR plus accumulated dividends from the grant date, times the number of SARs exercised. This value is divided by the Election Price to determine the number of stock units. The stock units and accumulated dividend units will be settled in Pfizer common stock on the SAR original settlement date, the seventh anniversary of grant. Read SEC document |
| November 11, 2021 Filed Nov 15, 2021 22:40 UTC |
Dolsten MikaelPresident R&D
|
Exercise / conversionCommon Stock | 64,841 | $27.34 | $1,772,752.94 |
DisclosureSEC source: 0001225208-21-013883 · doc4.xml · nonDerivative · entry 2 Dolsten Mikael · CIK 0001437590 · President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 280,934 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · shares: Represents the number of stock units received upon the exercise and conversion of previously granted stock appreciation rights (SARs), calculated by taking the change in Pfizer common stock price (20 trading day average ending on the exercise date (Election Price of $44.58)) less the grant price of the SAR plus accumulated dividends from the grant date, times the number of SARs exercised. This value is divided by the Election Price to determine the number of stock units. The stock units and accumulated dividend units will be settled in Pfizer common stock on the SAR original settlement date, the fifth anniversary of grant. Read SEC document |
| November 11, 2021 Filed Nov 15, 2021 22:40 UTC |
Dolsten MikaelPresident R&D
|
Exercise / conversionCommon Stock | 76,135 | $22.89 | $1,742,730.15 |
DisclosureSEC source: 0001225208-21-013883 · doc4.xml · nonDerivative · entry 1 Dolsten Mikael · CIK 0001437590 · President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 216,093 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the number of stock units received upon the exercise and conversion of previously granted stock appreciation rights (SARs), calculated by taking the change in Pfizer common stock price (20 trading day average ending on the exercise date (Election Price of $44.58)) less the grant price of the SAR plus accumulated dividends from the grant date, times the number of SARs exercised. This value is divided by the Election Price to determine the number of stock units. The stock units and accumulated dividend units will be settled in Pfizer common stock on the SAR original settlement date, the seventh anniversary of grant. Read SEC document |
| October 29, 2021 Filed Nov 2, 2021 15:46 UTC |
BOURLA ALBERTDirector · Chairman & CEO
|
GrantPhantom Stock Units SSP · Derivative | 11 | $43.74 | $481.14 |
DisclosureSEC source: 0001225208-21-013416 · doc4.xml · derivative · entry 1 BOURLA ALBERT · CIK 0001595703 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,350 Underlying: Common Stock · 11 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| October 29, 2021 Filed Nov 2, 2021 15:46 UTC |
DAMICO JENNIFER B.SVP & Controller
|
GrantPhantom Stock Units SSP · Derivative | 28 | $43.74 | $1,224.72 |
DisclosureSEC source: 0001225208-21-013417 · doc4.xml · derivative · entry 1 DAMICO JENNIFER B. · CIK 0001805617 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,100 Underlying: Common Stock · 28 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| October 29, 2021 Filed Nov 2, 2021 15:46 UTC |
JOHNSON RADY AExecutive Vice President
|
GrantPhantom Stock Units SSP · Derivative | 4 | $43.74 | $174.96 |
DisclosureSEC source: 0001225208-21-013418 · doc4.xml · derivative · entry 1 JOHNSON RADY A · CIK 0001594762 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,702 Underlying: Common Stock · 4 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| October 29, 2021 Filed Nov 2, 2021 15:46 UTC |
YOUNG JOHN DGroup President
|
GrantPhantom Stock Units SSP · Derivative | 10 | $43.74 | $437.40 |
DisclosureSEC source: 0001225208-21-013419 · doc4.xml · derivative · entry 1 YOUNG JOHN D · CIK 0001551792 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,316 Underlying: Common Stock · 10 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| October 15, 2021 Filed Oct 18, 2021 22:47 UTC |
YOUNG JOHN DGroup President
|
GrantPhantom Stock Units SSP · Derivative | 11 | $41.49 | $456.39 |
DisclosureSEC source: 0001225208-21-013133 · doc4.xml · derivative · entry 1 YOUNG JOHN D · CIK 0001551792 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,329 Underlying: Common Stock · 11 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| October 15, 2021 Filed Oct 18, 2021 22:47 UTC |
BOURLA ALBERTDirector · Chairman & CEO
|
GrantPhantom Stock Units SSP · Derivative | 12 | $41.49 | $497.88 |
DisclosureSEC source: 0001225208-21-013134 · doc4.xml · derivative · entry 1 BOURLA ALBERT · CIK 0001595703 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,380 Underlying: Common Stock · 12 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| October 15, 2021 Filed Oct 18, 2021 22:47 UTC |
DAMICO JENNIFER B.SVP & Controller
|
GrantPhantom Stock Units SSP · Derivative | 30 | $41.49 | $1,244.70 |
DisclosureSEC source: 0001225208-21-013135 · doc4.xml · derivative · entry 1 DAMICO JENNIFER B. · CIK 0001805617 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,079 Underlying: Common Stock · 30 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| October 15, 2021 Filed Oct 18, 2021 22:47 UTC |
JOHNSON RADY AExecutive Vice President
|
GrantPhantom Stock Units SSP · Derivative | 4 | $41.49 | $165.96 |
DisclosureSEC source: 0001225208-21-013136 · doc4.xml · derivative · entry 1 JOHNSON RADY A · CIK 0001594762 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,701 Underlying: Common Stock · 4 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| October 12, 2021 Filed Oct 13, 2021 19:46 UTC |
BOURLA ALBERTDirector · Chairman & CEO
|
GrantPhantom Stock Units SSP · Derivative | 46 | $41.85 | $1,925.10 |
DisclosureSEC source: 0001225208-21-013098 · doc4.xml · derivative · entry 1 BOURLA ALBERT · CIK 0001595703 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,361 Underlying: Common Stock · 46 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| October 12, 2021 Filed Oct 13, 2021 19:46 UTC |
DAMICO JENNIFER B.SVP & Controller
|
GrantPhantom Stock Units SSP · Derivative | 132 | $41.85 | $5,524.20 |
DisclosureSEC source: 0001225208-21-013099 · doc4.xml · derivative · entry 1 DAMICO JENNIFER B. · CIK 0001805617 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,048 Underlying: Common Stock · 132 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| October 12, 2021 Filed Oct 13, 2021 19:46 UTC |
JOHNSON RADY AExecutive Vice President
|
GrantPhantom Stock Units SSP · Derivative | 18 | $41.85 | $753.30 |
DisclosureSEC source: 0001225208-21-013100 · doc4.xml · derivative · entry 1 JOHNSON RADY A · CIK 0001594762 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,697 Underlying: Common Stock · 18 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.